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 Objective To determine the frequency of highly active antiretroviral 
therapy resistance mutations in the viral pol gene of human 
immunodeficiency virus–1 (HIV-1) genotypes that circulate in 
Hong Kong, by means of an in-house HIV-1 genotyping system.
 Design Retrospective study. 
 Setting Two HIV clinics in Hong Kong.
 Patients A modified in-house genotyping resistance test was used to 
sequence the partial pol gene in 1165 plasma samples from 965 
patients. The performance of our test was cross-compared with 
the US Food and Drug Administration–approved ViroSeq HIV-1 
genotyping system. The results of genotyping were submitted to 
the Stanford HIV-1 drug resistance database for analysis.
 Results The cost-effective in-house genotypic resistance test (US$40) 
demonstrated comparable performance to the US Food and 
Drug Administration–approved ViroSeq system. The detection 
limit of this in-house genotypic resistance test could reach 400 
copies/mL for both HIV-1 subtype B and CRF01_AE, which were 
the predominant genotypes in Hong Kong. Drug resistance 
mutations were detected only in post-treatment samples from 
treatment-failure patients. However, there was no significant 
difference in the frequency of drug resistance mutations between 
subtype B and CRF01_AE.
 Conclusion Our cost-effective in-house genotypic resistance test detected 
no significant difference in drug resistance–related mutations 
frequencies between HIV-1 subtype B and CRF01_AE in Hong 
Kong. A drug resistance–related mutations database for different 
HIV-1 genotypes should be established in Hong Kong to augment 
guidance for HIV treatment.
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New knowledge added by this study
• The newly developed test was applicable to various human immunodeficiency virus–1 (HIV-1) 
genotypes prevailing in Hong Kong.
Implications for clinical practice or policy
• Use of the in-house HIV-1 genotyping resistance test is recommended before initiation of 
appropriate highly active antiretroviral therapy.
Introduction
The use of highly active antiretroviral therapy (HAART) has proven remarkably effective 
in controlling the progression of human immunodeficiency virus (HIV) disease and thus 
prolonging survival.1 However, these benefits can be compromised by the development of 
antiretroviral drug resistance.2,3 
 There are currently more than 60 International AIDS Society (IAS)–defined 
antiretroviral drug resistance–related mutations (DRMs), which are associated with 
resistance to drugs belonging to the six US Food and Drug Administration (FDA)–approved 
antiretroviral classes.4 Genotypic resistance tests (GRTs) have been widely used as routine 
services for HIV-1 drug resistance monitoring in the developed countries.5 Due to the high 
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cost of using the FDA-approved commercial HIV-1 
genotyping system, resource-limited developing 
countries may not be inclined to provide this form of 
testing as a routine. 
 By means of this study, we tried to study the 
frequency of DRMs in HIV-1 genotypes that circulate 
in Hong Kong, using a cost-effective in-house HIV-1 
GRT suitable for use with both subtype B and non-B 
HIV-1 variants.
Methods
Sample collection
Between 2005 and 2009, 1165 plasma samples from 
965 HIV-infected patients were collected in two 
HIV clinics in Hong Kong. Single pre-treatment 
samples were available from 865 treatment-naïve 
patients, whereas paired pre-treatment and post-
treatment samples were available from 20 virologic 
treatment-responsive and 80 virologic treatment-
failure patients. Post-treatment samples were 
collected from 12 to 24 months after starting HAART 
with either two nucleoside reverse transcriptase 
inhibitors (NRTIs) plus one protease inhibitor (PI) 
or two NRTIs plus one non–nucleoside reverse 
transcriptase inhibitor (NNRTI). Virologic treatment 
responsiveness was defined as demonstration of 
a viral load of less than 400 copies/mL within 24 
weeks of initiating HAART and without any evidence 
of immunological or clinical failure. Virologic 
treatment failure in a patient was defined as the 
presence of a viral load of more than 1000 copies/mL 
on more than two occasions with or without 
associated immunological or clinical failure. 
Protease and reverse transcriptase nucleotide 
sequence determination
Viral RNA was extracted from each of the 500 μL 
patient plasma samples. The plasma samples were 
stored in -80°C and viral extraction was performed 
in batches; the samples were first centrifuged at 
20 000×g and 4°C for 90 minutes and then extracted 
using the QIAamp Viral RNA Extraction Kit (Qiagen, 
Hilden, Germany). The entire protease (PR) and 
the first 400 codons of the reverse transcriptase 
(RT) of all 1165 samples were generated by an in-
house genotyping method.6 The amplification and 
sequencing primers used in the in-house method 
had been modified from our previous protocol 
due to the high polymorphic nature of HIV, which 
weakened the binding efficiency of the previous 
primer sets. The modified primers were optimised 
for HIV-1 variants circulating in the Asia Pacific region 
(Table 1). Sequences were then generated by the ABI 
PRISM 3130xl Genetic Analyzer (Applied Biosystems, 
CA, US). Among the 1165 samples, 350 treatment-
naïve, 20 treatment-responsive and 80 treatment-
 目的 使用HIV-1基因型耐藥檢測的內部測試系統找出香港
HIV-1 pol基因中HAART耐藥基因變異的情況。
 設計 回顧研究。
 安排 香港兩間HIV診所。
 患者 使用一個改良了的基因型耐藥檢測的內部測試系統，
把965名HIV患者中的1165個血漿樣本作pol基因序列
分析。得出結果與美國食品藥品監督管理局（FDA）
認可的基因變異測試系統（ViroSeq HIV-1 genotyping 
system）作比較。最後把測試結果呈報美國斯坦福大
學HIV-1耐藥數據庫作分析用途。
 結果 我們所使用的病毒基因型耐藥內部測試系統價值40
美元，其表現可媲美FDA認可的基因變異測試系統
（ViroSeq）。這內部測試系統對於本港最常見的兩
種HIV-1亞型毒株（HIV-1 subtype B and CRF01_
AE）的檢測上限可達至每毫升400拷貝。耐藥變異只
在治療失敗的病人經治療後的血漿樣本中檢測得到。
至於兩種HIV-1亞型毒株（subtype B and CRF01_
AE）的耐藥變異頻率則無顯著分別。 
 結論 對於兩種HIV-1亞型毒株（subtype B and CRF01_
AE）耐藥基因變異的頻率，經過高成本效益的病毒基
因型耐藥內部系統測試，發現並無顯著分別。香港必
須要發展一套針對不同HIV-1基因型的數據庫，以加
強對於HIV病毒治療的指引。
使用一套耐藥基因型的內部測試系統找出香港人
類免疫缺陷病毒一型（HIV-1）高效抗逆轉病毒
治療（HAART）耐藥基因變異的情況
failure samples were also genotyped using an FDA-
approved ViroSeq HIV-1 Genotyping System (version 
2.0), as a means of evaluating the performance of the 
in-house GRT. 
TABLE 1. In-house primers used for reverse transcriptase–polymerase chain reaction 
(RT-PCR), nested PCR and cycle sequencing
Primer name Sequence (5’ > 3’) HXB2 position
First RT-PCR 
HIVGRT1F GCAAGRTTTTGGCBGARGCAATGAG 1867>1892
HIVGRT1R GACATTTATCACAGYWGGCTACTATTT 4359<4333
Nested PCR
HIVGRT2F GGAAAAAGGGCTGTTGGAAATGTG 2015>2038
HIVGRT2R TTAGTYTCCCTRYTAGCTGCCCCATC 3901<3876
Sequencing
HIVSEQF2 GCCTGAAAAYCCATAYAATACTCCA 2702>2726
HIVSEQF4 GAGAGACAGGCTAATTTTTTAGG 2071>2093
HIVSEQF5 ACACCTGCCAACATAATTGGA 2490>2510
HIVSEQR1 GGAGGGGTATTRACAAAYTCCCA 3811<3789
HIVSEQR2 TGGATTTTKTDHTCTAAARGGCTCT 3173<3099
HIVSEQR3 GGTACAGTGTCAATAGGACTAATTGGGAA 2575<2547
HIVSEQR4 CCATTCCTGGCTTTAATTTTACTG 2598<2575
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Quality assurance of the in-house genotyping test
The sensitivity and specificity of the in-house GRT 
were evaluated through participation in the TREAT 
Asia Quality Assurance Scheme (TAQAS) held by the 
National Serology Laboratory, Australia.7 A total of 
five testing panels with 25 proficiency testing samples 
were genotyped using the in-house system. They 
were clinical samples of different HIV-1 genotypes, 
collected from patients in different parts of the Asia-
Pacific region. The sequences were then compared 
with the reference results provided by the organiser. 
The detection limit of the in-house assay on subtype 
B and CRF01_AE was investigated using plasma 
samples with serial dilutions as follows: 20 000, 10 000, 
2000, 1000, 400, 200, 100 copies/mL.
Drug resistance analysis
The individual sequence fragments generated by the 
in-house system were aligned and manually edited 
with the Lasergene version 8.1 system (DNASTAR, 
Wisconsin, US). For the ViroSeq system–generated 
sequences, the ViroSeq HIV-1 Genotyping Software 
was used for sequence editing and alignment. 
A phylogenetic tree was plotted with the edited 
sequences, so as to prevent cross-contamination 
during amplification or DNA sequencing. All the 
edited sequences were submitted to the REGA 
Genotyping Tool version 2.0 for HIV genotyping 
and the Stanford HIVdb database (http://hivdb.
stanford.edu) for drug resistance interpretation.8,9 
The susceptibilities of 20 antiretroviral drugs were 
interpreted. They included: zidovudine (AZT), 
lamivudine (3TC), didanosine (ddI), stavudine (d4T), 
abacavir (ABC), emtricitabine (FTC), tenofovir (TDF), 
delavirdine (DLV), efavirenz (EFV), etravirine (ETR), 
nevirapine (NVP), atazanavir (ATV), darunavir (DRV), 
fosamprenavir (FPV), indinavir (IDV), lopinavir (LPV), 
ritonavir (RTV), nelfinavir (NFV), saquinavir (SQV) 
and tipranavir (TPV).
Results
Quality assurance of the in-house genotypic 
resistance test
With the five TAQAS HIV-1 proficiency panels, 
the in-house GRT–generated results consistently 
demonstrated over 95% concordance with the 
reference sequence results. The TAQAS panels 
included samples with multiple HIV-1 genotypes 
(subtype B, C and CRF01_AE), some of which carried 
DRMs in the PR/RT region. 
 Different aspects of the in-house and ViroSeq 
HIV-1 genotyping systems were compared in this 
study. Both systems required 2 to 3 days of processing 
time and similar equipment was used for processing. 
With respect to all 450 clinical samples, complete 
concordance in the DRM patterns was identified 
between the two systems. By genotyping the serially 
diluted HIV-1–positive plasma samples, the in-house 
GRT successfully amplified samples with viral loads 
down to 400 copies/mL on both clinical subtype B 
and CRF01_AE HIV-1 samples, which demonstrated 
comparable results to the FDA-approved ViroSeq 
genotyping system (recommended for samples with 
viral loads of >1000 copies/mL). However, the reagent 
cost for running the in-house system was around 
* Data are shown in No. of samples out of the total No. of patients receiving corresponding 
antiretroviral drug in the group, with % in brackets
† P values were calculated with Fisher’s exact test
TABLE 2. Frequency of the major drug resistance mutations in samples obtained from 
HIV-1 subtype B and CRF01_AE treatment-failure patients
Mutation HIV-1 subtype* P value†
CRF01_AE B
Reverse transcriptase
Nucleoside reverse 
transcriptase inhibitors
M41I/L 6/37 (16.2) 7/28 (25.0) 0.54
D67N 11/37 (29.7) 9/28 (32.1) 1.0
K70G/R 5/37 (13.5) 5/28 (17.9) 0.73
L210W 3/37 (8.1) 4/28 (14.3) 0.45
T215C/E/F/I/S/Y 8/37 (21.6) 11/28 (39.3) 0.17
K219E/N/Q 7/37 (18.9) 6/28 (21.4) 1.0
K65R 1/6 (16.7) 1/7 (14.3) 1.0
L74V 5/9 (55.6) 2/7 (28.6) 0.36
Q151M 1/9 (11.1) 1/7 (14.3) 1.0
M184I/V 34/39 (87.2) 25/29 (86.2) 1.0
Non-nucleoside reverse 
transcriptase inhibitors
K103N 4/15 (26.7) 12/15 (80.0) 0.0092
V106A/M 1/15 (6.7) 0/15 (0) 1.0
Y181C/I 5/15 (33.3) 4/15 (26.7) 1.0
G190A/E/S 5/15 (33.3) 2/15 (13.3) 0.39
Entire protease
L23I 0/26 (0) 1/24 (4.2) 0.48
D30N 0/26 (0) 5/24 (20.8) 0.0201
V32I 1/26 (3.8) 1/24 (4.2) 1.0
L33F 1/26 (3.8) 3/24 (12.5) 0.34
M46I/L 11/26 (42.3) 8/24 (33.3) 0.57
I47A/V 3/26 (11.5) 1/24 (4.2) 0.61
G48Q 0/26 (0) 1/24 (4.2) 0.48
I50L/V 1/26 (3.8) 0/24 (0) 1.0
I54A/L/M/V 5/26 (19.2) 5/24 (20.8) 1.0
L76V 2/26 (7.7) 0.24 (0) 0.49
V82A/F/T 3/26 (11.5) 4/24 (16.7) 0.70
I84V 5/26 (19.2) 1/24 (4.2) 0.19
N88D/S 3/26 (11.5) 4/24 (16.7) 0.70
L90M 4/26 (15.4) 7/24 (29.2) 0.31
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US$40 per sample, which was only one quarter the 
cost of using the ViroSeq system (US$160). 
Subtype distribution in Hong Kong
In this study, viral sequences of all 1165 samples 
were successfully sequenced by the in-house GRT. 
Among the 965 patients, 444 (46%) were infected with 
subtype B virus and 415 (43%) with the CRF01_AE 
virus. Another 99 patients were infected with other 
defined genotypes including subtype A1 (4 patients; 
0.4%), C (40 patients; 4.1%), D (2 patients; 0.2%), 
G (3 patients; 0.3%), CRF02_AG (7 patients; 0.7%), 
CRF07_BC (7 patients; 0.7%), CRF08_BC (6 patients; 
0.6%), CRF33_01B (2 patients; 0.2%), and other unique 
recombinant forms (35 patients; 3.6%).
Frequency of major drug resistance mutations
The GRT results from the samples of all treatment-
naïve and treatment-responsive patients revealed no 
IAS-defined major DRM in the viral pol gene.
 Regarding the 80 treatment-failure patients, 
they received NRTIs in their initial HAART regimen 
and at least one IAS-defined NRTI resistance–
related mutation was identified in the sequences of 
their post-treatment samples. The frequency of the 
major DRMs for NRTIs, NNRTIs, and PIs among the 
post-treatment samples of subtype B and CRF01_AE 
samples are presented in Table 2. In the RT region, 
thymidine analogue mutations (TAMs) which could 
decrease the susceptibility to AZT, d4T, ddI, ABC and 
TDF were identified in 43% (31/72) of the patients who 
had received AZT or d4T. The TAMs were generally 
more prevalent in patients with HIV-1 subtype B 
(50%; 14/28) compared to the CRF01_AE subtype 
(35%; 13/37), but this difference was not statistically 
significant (P=0.17-1.0). Among the different TAMs, 
T215C/E/F/I/S/Y was the most common. This mutation 
was also found in every sample that has developed 
the M41I/L mutation. 
 Regarding those who had received 3TC in their 
initial HAART regimen, a high proportion of subtype 
B (86%; 25/29) and CRF01_AE (87%; 34/39) patient 
samples showed the M184I/V mutation that causes 
high-level 3TC resistance.
 Among the 80 treatment-failure patients, 33 
(41%) including 15 subtype B, 15 CRF01_AE and 3 
other subtypes had exposure to NNRTI in their 
initial HAART regimen. A primary NNRTI resistance 
mutation K103N was identified in 16 of these 33 
NNRTI-treated patients (B: 80% [12/15]; CRF01_AE: 
27% [4/15]; others: 67% [2/3]). In subtype B viruses, 
K103N development was significantly greater than in 
CRF01_AE viruses (P=0.0092). Other primary NNRTI 
resistance mutations including V106A/M, Y181C/I and 
G190A/E/S were occasionally found in subtype B– 
and CRF01_AE–infected patients, who had received 
NNRTIs.
 Regarding another 47 patients who had 
received PIs in their HAART regimen, 27 (57%) of 
them carried viruses which had developed at least 
one major PI resistance mutation (B: 50% [12/24]; 
CRF01_AE: 54% [14/26]; others: 33% [1/3]). Most of 
the primary PI resistance mutations showed no 
significant difference between subtype B and in 
CRF01_AE viruses, except D30N. This NFV-induced 
major PI resistance mutation was identified in 21% 
of subtype B patients but not in any patient carrying 
HIV-1 with other genotypes (P=0.0201). The M46I/L 
mutation was the most commonly found major PI 
resistance mutation in this study. It was observed 
in 33% (8/24) of subtype B–infected and 42% (11/26) 
of CRF01_AE–infected patients who had exposure 
to IDV, LPV, NFV, RTV or SQV. The L90M mutation 
was also observed in 29% (7/24) of subtype B– and 
15% (4/26) of CRF01_AE–infected patients, who 
had received NFV or IDV treatment. Other major 
PI resistance mutations including L23I, V32I, L33F, 
I47A/V, G48Q, I50L/V, I54A/L/M/V, L76V, V82A/F/T, I84V 
and N88D/S were also observed in the sequences of 
the subtype B and CRF01_AE samples.
Discussion
Resorting to GRT has become an essential tool for 
HIV-1 drug resistance monitoring. Although the FDA-
approved genotyping has demonstrated high-quality 
performance on both subtype B and non-B HIV-1 
strains, the high running costs of their assays hinder 
their routine application in developing countries.6 
 This study introduced a modified in-house GRT, 
which had improved primer binding quality suitable 
for testing the increased degree of HIV-1 genetic 
diversity found in our locality.10 Its performance 
in the five TAQAS proficiency testing panels also 
indicated its high sensitivity for identifying multiple 
HIV-1 genotypes. 
 Owing to the low running cost of our in-house 
GRT (US$40) and comparable performance to the 
commercial FDA-approved ViroSeq HIV-1 genotyping 
system, it could be widely applied, especially in 
developing countries.
 Through the use of our in-house GRT in 
genotyping 1165 clinical samples in Hong Kong, 
we also revealed that the HIV-1 subtype B and 
CRF01_AE were the predominant genotypes in 
Hong Kong. Our previous report of a cohort 
collected between 2000 and 2004 yielded only 
subtype B, C and CRF01_AE viruses.11 However, 
the cohort in this study was collected from 2005 to 
2009, and included a greater variety of non-B 
subtypes and HIV-1 new recombinants. The current 
study is also consistent with the increasing genetic 
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diversity of HIV-1 previously reported in Hong 
Kong.10
 The absence of resistance mutations in all 
treatment-naïve and pre-treatment patient samples 
also demonstrates the low prevalence of primary 
resistance among HIV-1 patients in Hong Kong.12 
Evidently, all drug resistance mutations developed 
after starting HAART.
 The difference in the frequency of DRMs in 
HIV-1 subtype B and non-B viruses has been a debated 
topic for several years.11,13-17 Generally, most of the 
DRMs exhibit no significant difference in frequency 
in subtypes B and CRF01_AE viruses. Our study, 
however, demonstrated that when exposed to NRTI, 
the HIV-1 subtype B apparently had a higher chance 
of developing TAMs compared to HIV-1 CRF01_AE. 
In addition, a significantly higher rate of K103N 
development was observed in the former subtype.
 In conclusion, our cost-effective in-house GRT 
is suitable for the detection of low viral load and high 
genetic diversity HIV-1 samples circulating among 
developing countries in Asia. Although there is no 
significant difference in DRM frequencies between 
subtype B and CRF01_AE, a DRM database for 
different HIV-1 genotypes should be established as 
guide for management of HIV infection in our region.
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